Can precision psychiatry finally move beyond trial and error? By combining genomics, brain imaging, and digital biomarkers, the MAP-D initiative aims to redefine depression through biology rather than symptoms alone. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/can-precision-psychiatry-finally-move-beyond-trial-and-error-17426 Depression affects hundreds of millions of people worldwide and remains one of the leading causes of disability. However, there is still no single laboratory test, imaging scan, or molecular marker that can objectively diagnose the disorder, distinguish biologically distinct forms of depression, or predict which treatment would be most effective for an individual patient. Instead, clinicians rely largely on symptom-based questionnaires, trapping many patients in a frustrating cycle of trial and error that can leave patients waiting months or years to find an effective therapy.